United States

Infinity Pharmaceuticals Inc (INFI.OQ)

INFI.OQ on NASDAQ Stock Exchange Global Select Market

20 Jan 2017
Change (% chg)

$0.45 (+29.03%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for INFI.OQ


Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145,... (more)


Beta: 2.49
Market Cap(Mil.): $77.08
Shares Outstanding(Mil.): 49.73
Dividend: --
Yield (%): --


  INFI.OQ Industry Sector
P/E (TTM): -- 44.51 30.50
EPS (TTM): -0.94 -- --
ROI: -24.09 -1.38 14.85
ROE: -39.33 -1.00 16.27

BRIEF-Infinity expects net loss for 2017 in the range of $40 mln to $50 mln

* Infinity Pharmaceuticals Inc - expects to end 2017 with a year-end cash and investments balance ranging from $40 million to $50 million

Jan 09 2017

BRIEF-Bristol-Myers, Infinity Pharma to evaluate Opdivo with IPI-549 in advanced solid tumors

* Bristol-Myers Squibb and infinity pharmaceuticals announce clinical collaboration to evaluate Opdivo (nivolumab) in combination with IPI-549 in advanced solid tumors

Nov 09 2016

BRIEF-Verastem licenses duvelisib from infinity pharmaceuticals

* Verastem is obligated to pay to infinity up to $28 million in milestones

Nov 02 2016

BRIEF-Verastem licenses Duvelisib from Infinity Pharmaceuticals

* Verastem inc says under terms of license agreement, Verastem is obligated to pay to Infinity up to $28 million in milestones Source text for Eikon: Further company coverage:

Nov 02 2016

BRIEF-Infinity Pharma Q2 earnings per share $1.05

* Infinity provides company update and reports second quarter 2016 financial results

Aug 09 2016

Earnings vs. Estimates